Envoyer la notice par courriel: NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY